Live streptomycin-dependent Pasteurella multocida vaccine for the prevention of hemorrhagic septicemia.
A type B Pasteurella multocida was used for the development of a streptomycin-dependent (StrD) vaccine. Pasteurella multocida R-473, a hemorrhagic septicemia strain, was mutagenized with N-methyl-N'-nitro-N-nitrosoguanidine to increase the likelihood of encountering a StrD mutant and was plated on agar containing 400 microgram of streptomycin/ml. Replica plating was used to differentiate dependent from resistant colonies. Mice and rabbits were vaccinated with a StrD mutant and 21 days later, were challenge exposed, along with unvaccinated controls, with the wild type R-473. Protection of greater than 4 logs was shown for the vaccinated mice. All vaccinated rabbits were protected and all nonvaccinated controls succumbed to a challenge exposure of 500 or 1,000 LD50.
D000818:Animals; D001428:Bacterial Vaccines / Q000008:administration & dosage; D002417:Cattle; D005260:Female; D006470:Hemorrhage / Q000517:prevention & control / Q000662:veterinary*; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D008769:Methylnitronitrosoguanidine / Q000494:pharmacology; D051379:Mice; D009154:Mutation; D010325:Pasteurella / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D010326:Pasteurella Infections / Q000517:prevention & control / Q000662:veterinary*; D011817:Rabbits; D018805:Sepsis / Q000517:prevention & control / Q000662:veterinary*; D013307:Streptomycin / Q000378:metabolism*
D001428:Bacterial Vaccines; D008769:Methylnitronitrosoguanidine; D013307:Streptomycin